Correction to: Oncogene https://doi.org/10.1038/onc.2009.479, published online 18 January 2010
Following the publication of this article, the authors wish to update the ‘Conflict of interest’ statement as follows:
The University of British Columbia submitted patent applications on apatorsen, an antisense inhibitor of Hsp27, listing MEG and PR as inventors. This IP was licensed to OncoGenex Technologies, a Vancouver-based biotechnology company in which MEG had founding shares. The other authors have no competing interests.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Additional information
The original article can be found online at https://doi.org/10.1038/onc.2009.479.
Rights and permissions
About this article
Cite this article
Andrieu, C., Taieb, D., Baylot, V. et al. Correction: Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E. Oncogene 44, 3151 (2025). https://doi.org/10.1038/s41388-025-03531-9
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41388-025-03531-9
